Knight Therapeutics (TSE:GUD) released its quarterly earnings data on Thursday. The company reported C$0.04 EPS for the quarter, beating the consensus estimate of C$0.03 by C$0.01, Morningstar.com reports. The business had revenue of C$3.89 million for the quarter, compared to analysts’ expectations of C$2.55 million.
Knight Therapeutics stock opened at C$7.55 on Friday. Knight Therapeutics has a one year low of C$7.36 and a one year high of C$8.81. The firm has a market cap of $1.08 billion and a P/E ratio of 34.79.
Separately, Raymond James reaffirmed an “outperform” rating and set a C$10.25 price objective on shares of Knight Therapeutics in a research report on Wednesday, January 16th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of C$10.06.
About Knight Therapeutics
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.